Alphanate in Immune Tolerance Induction Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

September 18, 2020

Study Completion Date

September 18, 2020

Conditions
Hemophilia A, Congenital
Interventions
BIOLOGICAL

Alphanate

Bolus IV injection.

Trial Locations (20)

6132

A.O.U. Santa Maria della Misericordia Perugia, Perugia

27517

University of North Carolina at Chapel Hill, Hemophilia and Thrombosis Center, Chapel Hill

28046

Hospital Universitario La Paz, Madrid

30322

Emory University, Atlanta

40536

University of Kentucky, Lexington

41013

Hospital Universitario Virgen del Rocio, Seville

46026

Hospital Universitari i Politecnic La Fe, Valencia

50134

Azienda Ospedaliera Universitaria Careggi, Florence

55404

Childrens Hospital and Clinics of Minnesota, Minneapolis

64108

The Childrens Mercy Hospital, Kansas City

98101

Seattle Children's Hospital, Seattle Children's Research Institute, Seattle

191186

Center for Hemophilia Treatment St.-Petersburg, Saint Petersburg

400022

Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai

411001

B. J. Govt. Medical College & Sassoon Hospital, Pune

610027

FGUs Hospital - Kirov Scientific Research Institute, Kirov

650061

Kemerovo Regional Clinical Hospital, Kemerovo

08901

Robert Wood Johnson Medical Group, New Brunswick

07112

Newark Beth Israel Medical Center & Children's Hospital of New Jersey, Newark

L8N-3Z5

McMaster Children's Hospital, Hamilton

00161

Universita degli Studi di Roma La Sapienza, Roma

Sponsors
All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

Grifols Therapeutics LLC

INDUSTRY